NEW ORLEANS–(Organization WIRE)–Former Legal professional Common of Louisiana Charles C. Foti, Jr., Esq. and the legislation agency of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc. (NasdaqGS: EPZM) to Ipsen S.A. (OTC: IPSEY). Under the phrases of the proposed transaction, shareholders of Epizyme will acquire only $1.45 in money moreover a CVR (Contingent Price Suitable) of $1.00 for every share of Epizyme that they possess. KSF is looking for to figure out no matter if this consideration and the system that led to it are adequate, or no matter if the thing to consider undervalues the Corporation.
If you think that this transaction undervalues the Corporation and/or if you would like to discuss your authorized legal rights about the proposed sale, you may, without obligation or value to you, e-mail or connect with KSF Managing Partner Lewis S. Kahn (firstname.lastname@example.org) toll cost-free at any time at 855-768-1857, or go to https://www.ksfcounsel.com/scenarios/nasdaqgs-epzm/ to understand more.
Be sure to be aware that the merger is structured as a tender supply, these that time may perhaps be of the essence.
To understand far more about KSF, whose companions include the Former Louisiana Lawyer General, go to www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis S. Kahn, Controlling Associate